Loading TEM detail
Loading ticker data...
Loading TEM detail
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023.
Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Chart data unavailable
Tempus AI rides on diagnostics growth, AI-driven data demand, and pricing gains - but persistent losses and valuation questions complicate the buy-or-sell call.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead's oncology pipeline. To date, Gilead has leveraged Tempus' extensive repository of de-identified multimodal data to inform a range of oncology R&D initiatives, including trial design, indication selection, biomarker strategy.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16. Tempus' Chief Financial Officer Jim Rogers, will participate in a fireside discussion at the conference on Tuesday, April 14 at 11:45 am ET. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision me.
Tempus AI's data arm surges with 69.5% Insights growth, $1.1B+ contracts, and AI-driven expansion fueling strong revenue outlook and customer retention gains.
Aberdeen Group plc grew its holdings in shares of Tempus AI, Inc. (NASDAQ: TEM) by 64.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 263,004 shares of the company's stock after purchasing an additional 102,878 shares during the period. Aberdeen Group
Step Capital Management Pte. Ltd. purchased a new position in shares of Tempus AI, Inc. (NASDAQ: TEM) in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 20,000 shares of the company's stock, valued at approximately $1,181,000. Tempus AI makes up approximately 0.5%
Tempus AI (NASDAQ: TEM - Get Free Report) and Alternate Health (OTCMKTS:AHGIF - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Insider and Institutional Ownership 24.2% of Tempus AI
Tempus AI is a diagnostics and data platform leveraging a large healthcare dataset to inform clinical decision-making. Strong 2025 performance driven by diagnostics growth, oncology re-acceleration, and Ambry Genetics acquisition. AI model reaching “critical mass” with 450+ petabytes of data, enabling new product expansion.
TEM jumps after ALERT trial shows EHR alerts boost timely valve care, improving evaluations and interventions for aortic stenosis and MR patients.
TEM's diagnostics arm surges on oncology demand, MRD adoption and rising pricing, with 2026 growth set to stay strong as sequencing and reimbursement expand.
Specifically, the study found a 40% relative increase in life-saving valve procedures and a 27% increase in multidisciplinary heart team evaluations within just 90 days.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from the ALERT (Addressing undertreatment and heaLth Equity in aortic stenosis and mitral regurgitation using an integrated ehR plaTform) trial, which were recently presented at the American College of Cardiology's 75th Annual Scientific Session & Expo. The study, conducted in collaboration with Medtronic, found that automated electr.
Tempus AI TEM and Doximity DOCS are two well-established players in the Medical Information Systems industry, each with distinct niche. Tempus is focused on advancing precision medicine through artificial intelligence.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduces a next-generation cryogenic transmission electron microscope (cryo-TEM) designed to help scientists understand structural biology with greater clarity — now accessible in more lab environments than ever before. The Thermo Scientific™ Glacios™ 3 Cryo-TEM offers researchers the next major advancement in 200 kV imaging and structural analysis. Cryogenic electron microscopy (cryo-EM), an.
AI-powered drug discovery and development is now a possibility. Artificial intelligence is also able to help caregivers navigate a complex collection of ever-changing treatment options.
